ALX Oncology (NASDAQ:ALXO) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research note released on Friday morning,Benzinga reports. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2025 earnings at ($2.21) EPS.

Other analysts have also issued reports about the stock. Jefferies Financial Group lowered shares of ALX Oncology from a “buy” rating to a “hold” rating and cut their target price for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. HC Wainwright cut their target price on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, ALX Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $3.50.

ALX Oncology Stock Down 7.1 %

Shares of NASDAQ:ALXO opened at $1.52 on Friday. The firm’s 50-day moving average is $1.61 and its two-hundred day moving average is $2.42. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology has a 1 year low of $1.19 and a 1 year high of $17.83. The firm has a market capitalization of $79.90 million, a PE ratio of -0.51 and a beta of 0.98.

Insider Activity at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was purchased at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the acquisition, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 14,443 shares of company stock valued at $23,309 over the last three months. 33.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ALX Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its holdings in shares of ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology in the second quarter valued at approximately $63,000. GSA Capital Partners LLP acquired a new stake in shares of ALX Oncology in the third quarter valued at approximately $88,000. Barclays PLC boosted its holdings in shares of ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after acquiring an additional 42,185 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in shares of ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after acquiring an additional 6,080 shares during the period. 97.97% of the stock is owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.